Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Up 467.7% in June

Virax Biolabs Group Limited (NASDAQ:VRAX) was the target of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 266,800 shares, a growth of 467.7% from the May 31st total of 47,000 shares. Based on an average daily trading volume, of 1,390,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 15.4% of the company’s stock are short sold.

Virax Biolabs Group Stock Down 4.1 %

Shares of VRAX opened at $1.18 on Friday. Virax Biolabs Group has a one year low of $0.60 and a one year high of $4.30. The business has a fifty day moving average of $1.07 and a 200 day moving average of $1.03.

Institutional Trading of Virax Biolabs Group

An institutional investor recently bought a new position in Virax Biolabs Group stock. Armistice Capital LLC acquired a new position in Virax Biolabs Group Limited (NASDAQ:VRAX) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 121,999 shares of the company’s stock, valued at approximately $178,000. Armistice Capital LLC owned 7.87% of Virax Biolabs Group as of its most recent SEC filing. Institutional investors and hedge funds own 8.61% of the company’s stock.

Virax Biolabs Group Company Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.